Chapter 37 : Therapy of Invasive Aspergillosis: Current Consensus and Controversies

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Therapy of Invasive Aspergillosis: Current Consensus and Controversies, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815523/9781555814380_Chap37-1.gif /docserver/preview/fulltext/10.1128/9781555815523/9781555814380_Chap37-2.gif


Invasive aspergillosis (IA) has emerged as an important infection, accounting for 20 to 40% of systemic fungal infections in patients with acute leukemia, 10 to 20% in blood and marrow transplant (BMT) recipients, and 5 to 15% in solid organ transplant recipients. This chapter provides a conceptual framework for the consensus and controversies in primary and salvage therapies for this infection. A large randomized multicenter study comparing the triazole voriconazole (VRC) to amphotericin-deoxycholate (DAMB; given at relatively high doses of 1 to 1.5 mg/kg of body weight/day), followed by other licensed antifungal therapy (mostly lipid formulations of AMB) for patients with lack of response or toxicity, showed a survival advantage in patients randomized to the VRC arm. The modern way of giving AMB-based therapy, especially if a patient is to be committed to weeks or even months of therapy, is with lipid AMB formulations, as these agents have lower nephrotoxicity and infusion related toxicity. Residual cavitary lesions, especially those containing fungus balls, after successful antifungal therapy may cause late exsanguinating hemorrhage or reactivation of infection during subsequent myelosuppressive chemotherapy. Advancements in early diagnosis by CT and the introduction of effective agents have improved response rates of primary antifungal therapy.

Citation: Kontoyiannis D, Marr K. 2009. Therapy of Invasive Aspergillosis: Current Consensus and Controversies, p 491-500. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch37
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1.
Figure 1.

Primary therapy of IA.

Citation: Kontoyiannis D, Marr K. 2009. Therapy of Invasive Aspergillosis: Current Consensus and Controversies, p 491-500. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch37
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2.
Figure 2.

Pharmacologic options for salvage therapy of IA with VRC monotherapy.

Citation: Kontoyiannis D, Marr K. 2009. Therapy of Invasive Aspergillosis: Current Consensus and Controversies, p 491-500. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch37
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3.
Figure 3.

Factors influencing individualization of therapy in IA.

Citation: Kontoyiannis D, Marr K. 2009. Therapy of Invasive Aspergillosis: Current Consensus and Controversies, p 491-500. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch37
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Aliff, T. B.,, P. G. Maslak,, J. G. Jurcic,, M. L. Heaney,, K. N. Cathcart,, K. A. Sepkowitz, and, M. A. Weiss. 2003. Refractory Aspergillus pneumonia in patients with acute leukemia. Cancer 97: 10251032.
2. Arthur, R. R.,, R. H. Drew, and, J. R. Perfect. 2004. Novel modes of antifungal drug administration. Expert Opin. Investig. Drugs 13: 903932.
3. Balajee, S. A.,, J. L. Gribskov,, E. Hanley,, D. Nickle, and, K. A. Marr. 2005. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot. Cell 4: 625632.
4. Becker, M. J.,, S. de Marie,, M. Fens,, W. C. J. Hop,, H. A. Verbrugh, and, I. Bakker-Woudenberg. 2002. Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response. J. Antimicrob. Chemother. 49: 813820.
5. Ben-Ami, R.,, R. E. Lewis, and, D. P. Kontoyiannis. 2008. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin. Infect. Dis. 47: 226235.
6. Boucher, H. W.,, A. H. Groll,, C. C. Chiou, and, T. J. Walsh. 2004. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 64: 19972020.
7. Cagnoni, P. J.,, T. J. Walsh,, M. M. Prendergast,, D. Bodensteiner,, S. Hiemenz,, R. N. Greenberg,, C. A. Arndt,, M. Schuster,, N. Seibel,, V. Yeldandi, and, K. B. Tong. 1997. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Clin. Oncol. 18: 24762483.
8. Caillot, D. 2003. Intravenous itraconazole followed by oral itracona-zole for the treatment of amphotericin B-refractory invasive pulmonary aspergillosis. Acta Haematol. 109: 111118.
9. Caillot, D.,, O. Casasnovas,, A. Bernard,, J. F. Couaillier,, C. Durand,, B. Cuisenier,, E. Solary,, F. Piard,, T. Petrella,, A. Bonnin,, G. Couil-lault,, M. Dumas, and, H. Guy. 1997. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J. Clin. Oncol. 15: 139147.
10. Caillot, D.,, A. Thiebaut,, R. Herbrecht,, S. de Botton,, A. Pigneux,, F. Bernard,, J. Larche,, F. Monchecourt,, S. Alfandari, and, L. Mahi. 2007. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 110: 27402746.
11. Chamilos, G., and, D. P. Kontoyiannis. 2006. Defining the diagnosis of invasive aspergillosis. Med. Mycol. 44: S163S172.
12. Chamilos, G.,, R. E. Lewis, and, D. P. Kontoyiannis. 2008. Delaying amphotericin B-based front-line therapy significantly increases mortality in hematologic malignancy patients with zygomycosis. Clin. Infect. Dis. 47: 503509.
13. Chamilos, G.,, M. Luna,, R. E. Lewis,, G. P. Bodey,, R. Chemaly,, J. J. Tarrand,, A. Safdar,, I. I. Raad, and, D. P. Kontoyiannis. 2006. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 91: 986989.
14. Chamilos, G.,, E. M. Marom,, R. E. Lewis,, M. S. Lionakis, and, D. P. Kontoyiannis. 2005. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin. Infect. Dis. 41: 6066.
15. Cornely, O. A.,, J. Maertens,, M. Bresnik,, R. Ebrahimi,, A. J. Ullmann,, E. Bouza,, C. P. Heussel,, O. Lortholary,, C. Rieger,, A. Boehme,, M. Aoun,, H. A. Horst,, A. Thiebaut,, M. Ruhnke,, D. Reichert,, N. Vi-anelli,, S. W. Krause,, E. Olavarria, and, R. Herbrecht. 2007. Lipo-somal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 44: 12891297.
16. Denning, D. W.,, P. Ribaud,, N. Milpied,, D. Caillot,, R. Herbrecht,, E. Thiel,, A. Haas,, M. Ruhnke, and, H. Lode. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34: 563571.
17. Greene, R. E.,, H. T. Schlamm,, J. W. Oestmann,, P. Stark,, C. Durand,, 0. Lortholary,, J. R. Wingard,, R. Herbrecht,, P. Ribaud,, T. F. Patterson,, P. F. Troke,, D. W. Denning,, J. E. Bennett,, B. E. de Pauw, and, R. H. Rubin. 2007. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin. Infect. Dis. 44: 373379.
18. Groll, A. H.,, S. C. Piscitelli, and, T. J. Walsh. 1998. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. 44: 343500.
19. Hachem, R. Y.,, D. P. Kontoyiannis,, M. R. Boktour,, C. Afif,, C. Cook-sley,, G. P. Bodey,, I. Chatzinikolaou,, C. Perego,, H. M. Kantarjian, and, I. I. Raad. 2004. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 101: 15941600.
20. Herbrecht, R.,, D. W. Denning,, T. F. Patterson,, J. E. Bennett,, R. E. Greene,, J. W. Oestmann,, W. V. Kern,, K. A. Marr,, P. Ribaud,, O. Lortholary,, R. Sylvester,, R. H. Rubin,, J. R. Wingard,, P. Stark,, C. Durand,, D. Caillot,, E. Thiel,, P. H. Chandrasekar,, M. R. Hodges,, H. T. Schlamm,, P. F. Troke, and, B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347: 408415.
21. Hohl, T. M., and, M. Feldmesser. 2007. Aspergillus fumigatus: principles of pathogenesis and host defense. Eukaryot. Cell 6: 19531963.
22. Kontoyiannis, D. P., and, G. P. Bodey. 2002. Invasive aspergillosis in 2002: an update. Eur. J. Clin. Microbiol. Infect. Dis. 21: 161172.
23. Kontoyiannis, D. P.,, R. Hachem,, R. E. Lewis,, G. A. Rivero,, H. A. Torres,, J. Thornby,, R. Champlin,, H. Kantarjian,, G. P. Bodey, and, I. I. Raad. 2003a. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98: 292299.
24. Kontoyiannis, D. P.,, R. E. Lewis,, M. S. Lionakis,, N. D. Albert,, G. S. May, and, I. I. Raad. 2003b. Sequential exposure of Aspergillus fumigatus to itraconazole and caspofungin: evidence of enhanced in vitro activity. Diagn. Microbiol. Infect. Dis. 47: 415419.
25. Kontoyiannis, D. P., and, R. E. Lewis. 2006. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect. Dis. Clin. North Am. 20: 581607.
26. Kontoyiannis, D. P., and, R. E. Lewis. 2004. Toward more effective antifungal therapy: the prospects of combination therapy. Br. J. Haematol. 126: 165175.
27. Kontoyiannis, D. P.,, M. S. Lionakis,, R. E. Lewis,, G. Chamilos,, M. Healy,, C. Perego,, A. Safdar,, H. Kantarjian,, R. Champlin,, T. J. Walsh, and, I. I. Raad. 2005. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 191: 13501360.
28. Latgé, J. P. 1999. Aspergillus fumigatus and aspergillosis. Clin. Micro-biol. Rev. 12: 310350.
29. Lewis, R. E. 2008. What is the “therapeutic range” for voriconazole? Clin. Infect. Dis. 46: 212214.
30. Lewis, R. E.,, G. Liao,, J. Hou,, G. Chamilos,, R. A. Prince, and, D. P. Kontoyiannis. 2007. A comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 51: 12531258.
31. Lionakis, M. S.,, R. E. Lewis,, G. Chamilos, and, D. P. Kontoyiannis. 2005. Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy. Pharmacotherapy 25: 11741180.
32. Maertens, J.,, I. Raad,, G. Petrikkos,, M. Boogaerts,, D. Selleslag,, F. B. Petersen,, C. A. Sable,, N. A. Kartsonis,, A. Ngai,, A. Taylor,, T. F. Patterson,, D. W. Denning, and, T. J. Walsh. 2004. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39: 15631571.
33. Marr, K. A.,, S. A. Balajee,, L. McLaughlin,, M. Tabouret,, C. Bentsen, and, T. J. Walsh. 2004a. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J. Infect. Dis. 190: 641649.
34. Marr, K. A.,, M. Boeckh,, R. A. Carter,, H. W. Kim, and, L. Corey. 2004b. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39: 797802.
35. Marr, K. A.,, M. Laverdiere,, A. Gugel, and, W. Leisenring. 2005. Antifungal therapy decreases sensitivity of the Aspergillus galactoman-nan enzyme immunoassay. Clin. Infect. Dis. 40: 17621769.
36. Martino, R.,, R. Parody,, T. Fukuda,, J. Maertens,, K. Theunissen,, A. Ho,, G. J. Mufti,, N. Kroger,, A. R. Zander,, D. Heim,, M. Palu-szewska,, D. Selleslag,, K. Steinerova,, P. Ljungman,, S. Cesaro,, A. Nightnen,, C. Cordonnier,, L. Vazquez,, M. Lopez-Duaerte,, J. Lopez,, R. Cabreara,, M. Rovira,, S. Neuburger,, O. Cornely,, A. E. Hunter,, K. A. Marr,, H. J. Dornbusch, and, H. Einsele. 2006. Impact of the intensity of the prettransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 108: 29282936.
37. Mennink-Kersten, M. A., and, P. E. Verweij. 2006. Non-culture-based diagnostics for opportunistic fungi. Infect. Dis. Clin. North Am. 20: 711727.
38. Miceli, M. H.,, J. Maertens,, K. Buve,, M. Grazziutti,, G. Woods,, M. Rahman,, B. Barlogie, and, E. J. Anaissie. 2007. Immune reconsti-tution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, de- scription, and clinical and research implications. Cancer 110: 112120.
39. Offner, F.,, C. Cordonnier,, P. Ljungman,, H. G. Prentice,, D. Engelhard,, D. De Bacquer,, F. Meunier, and, B. De Pauw. 1998. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin. Infect. Dis. 26: 10981103.
40. Ostrosky-Zeichner, L.,, K. A. Marr,, J. H. Rex, and, S. H. Cohen. 2003. Amphotericin B: time for a new “gold standard”. Clin. Infect. Dis. 37: 415425.
41. Pascual, A.,, T. Calandra,, S. Bolay,, T. Buclin,, J. Bille, and, O. Mar-chetti. 2007. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves safety and efficacy outcomes. Clin. Infect. Dis. 46: 201211.
42. Patterson, T. F.,, H. W. Boucher,, R. Herbrecht,, D. W. Denning,, O. Lortholary,, P. Ribaud,, R. H. Rubin,, J. R. Wingard,, B. DePauw,, H. T. Schlamm,, P. Troke, and, J. E. Bennett. 2005. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin. Infect. Dis. 41: 14481452.
43. Patterson, T. F.,, W. R. Kirkpatrick,, M. White,, J. W. Hiemenz,, J. R. Wingard,, B. Dupont,, M. G. Rinaldi,, D. A. Stevens, and, J. R. Gray-bill. 2000. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine 79: 250260.
44. Raad, I. I.,, H. A. Hanna,, M. Boktour,, Y. Jiang,, H. Torres,, C. Afif,, D. P. Kontoyiannis, and, R. Y. Hachem. 2008. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 22: 496503.
45. Safdar, A.,, G. Rodriguez,, N. Ohmagari,, D. P. Kontoyiannis,, K. V. Rolston,, I. I. Raad, and, R. E. Champlin. 2005. The safety of interferon-gamma-1b therapy for invasive fungal infections after he-matopoietic stem cell transplantation. Cancer 103: 731739.
46. Safdar, A.,, G. H. Rodriguez,, B. Lichtiger,, B. F. Dickey,, D. P. Kontoyiannis,, E. J. Freireich,, E. J. Shpall,, I. I. Raad,, H. M. Kantarjian, and, R. E. Champlin. 2006. Recombinant interferon ^1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 106: 26642671.
47. Segal, B. H.,, R. Herbrecht,, D. A. Stevens,, L. Ostrosky-Zeichner,, J. Sobel,, C. Viscoli,, T. J. Walsh,, J. Maertens,, T. F. Patterson,, J. R. Perfect,, B. Dupont,, J. R. Wingard,, T. Calandra,, C. A. Kauffman,, J. R. Graybill,, L. R. Baden,, P. G. Pappas,, J. E. Bennett,, D. P. Kontoyiannis,, C. Cordonnier,, M. A. Viviani,, J. Bille,, N. G. Almyroudis,, L. J. Wheat,, W. Graninger,, E. J. Bow,, S. M. Holland,, B. J. Kullberg,, W. E. Dismukes, and, B. E. De Pauw. 2008. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin. Infect. Dis. 47: 674683.
48. Singh, N.,, A. P. Limaye,, G. Forrest,, N. Safdar,, P. Munoz,, K. Pursell,, S. Houston,, F. Rosso,, J. G. Montoya,, P. Patton,, R. Del Busto,, J. M. Aguado,, R. A. Fisher,, G. B. Klintmalm,, R. Miller,, M. M. Wagener,, R. E. Lewis,, D. P. Kontoyiannis, and, S. Husain. 2006. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, mul-ticenter, observational study. Transplantation 81: 320326.
49. Sipsas, N. V., and, D. P. Kontoyiannis. 2006. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin. Infect. Dis. 42: 15841591.
50. Steinbach, W. J.,, D. K. Benjamin, Jr.,, D. P. Kontoyiannis,, J. R. Perfect,, I. Lutsar,, K. A. Marr,, M. S. Lionakis,, H. A. Torres,, H. Jafri, and, T. J. Walsh. 2004. Infections due to Aspergillus terreus: a multi-center retrospective analysis of 83 cases. Clin. Infect. Dis. 39: 192198.
51. Stevens, D. A., and, J. Y. Lee. 1997. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch. Intern. Med. 157: 18571862.
52. Trifilio, S.,, G. Pennick,, J. Pi,, J. Zook,, M. Golf,, K. Kaniecki,, S. Singhal,, S. Williams,, J. Winter,, M. Tallman,, L. Gordon,, O. Frankfurt,, A. Evens, and, J. Mehta. 2007a. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109: 15321535.
53. Trifilio, S.,, S. Singhal,, S. Williams,, O. Frankfurt,, L. Gordon,, A. Evens,, J. Winter,, M. Tallman,, J. Pi, and, J. Mehta. 2007b. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 40: 451456.
54. Upton, A.,, K. Kirby,, P. Carpenter,, M. Boeckh, and, K. A. Marr. 2007. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin. Infect. Dis. 44: 531540.
55. Verweij, P. E.,, E. Mellado, and, W. J. Melchers. 2007a. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356: 14811483.
56. Verweij, P. E.,, L. van Die, and, J. P. Donnelly. 2007b. Halo sign and improved outcome. Clin. Infect. Dis. 44: 16661667.
57. Walsh, T. J.,, E. J. Anaissie,, D. W. Denning,, R. Herbrecht,, D. P. Kon-toyiannis,, K. A. Marr,, V. A. Morrison,, B. H. Segal,, W. J. Steinbach,, D. A. Stevens,, J. van Burik,, J. R. Wingard, and, T. F. Patterson. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46: 327360.
58. Walsh, T. J.,, J. W. Hiemenz,, N. Seible,, J. R. Perfect,, G. Horwith,, L. Lee,, J. L. Silber,, M. J. DiNubile,, A. Reboli,, E. Bow,, J. Lister, and, E. J. Anaissie. 1998. Amphotericin B lipid complex in immunocompromised patients with invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 26: 13831396.
59. Walsh, T. J.,, I. Raad,, T. F. Patterson,, P. Chandrasekar,, G. R. Don-owitz,, R. Graybill,, R. E. Greene,, R. Hachem,, S. Hadley,, R. Her-brecht,, A. Langston,, A. Louie,, P. Ribaud,, B. H. Segal,, D. A. Stevens,, J. A. van Burik,, C. S. White,, G. Corcoran,, J. Gogate,, G. Krishna,, L. Pedicone,, C. Hardalo, and, J. R. Perfect. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44: 212.
60. Wheeler, R. T., and, G. R. Fink. 2006. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog. 2: e35.
61. Wingard, J. R. 2002. Lipid formulations of amphotericins: are you a lumper or a splitter? Clin. Infect. Dis. 35: 891895.
62. Wingard, J. R.,, M. H. White,, E. J. Anaissie,, J. T. Rafalli,, J. L. Goodman, and, A. C. Arieta. 1999. A randomized double blind study of Ambisome and Abelcet in febrile neutropenic patients, abstr. 015. Progr. Abstr. Focus Fungal Infect. IX, San Diego, CA, 18 to 20 March 1999. Imedex, Alpharetta, GA.
63. Woods, G.,, M. H. Miceli,, M. L. Grazziutti,, W. Zhao,, B. Barlogie, and, E. Anaissie. 2007. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 110: 830834.
64. Yeghen, T.,, C. C. Kibbler,, H. G. Prentice,, L. A. Berger,, R. K. Wal-lesby,, P. H. M. McWhinney,, F. C. Lampe, and, S. Gillespie. 2000. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin. Infect. Dis. 31: 859868.


Generic image for table
Table 1.

Systemic antifungal therapies as choices in the treatment of aspergillosis

Citation: Kontoyiannis D, Marr K. 2009. Therapy of Invasive Aspergillosis: Current Consensus and Controversies, p 491-500. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch37
Generic image for table
Table 2.

Outline for the treatment of IA

Citation: Kontoyiannis D, Marr K. 2009. Therapy of Invasive Aspergillosis: Current Consensus and Controversies, p 491-500. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch37

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error